Opendata, web and dolomites

SWEETBULLETS SIGNED

Sweet Theranostics in Bitter Infections - Seek and Destroy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SWEETBULLETS project word cloud

Explore the words cloud of the SWEETBULLETS project. It provides you a very rough idea of what is the project "SWEETBULLETS" about.

pathogenic    optimization    groups    exposed    extendable    clinically    pathogen    drug    treatments    charging    infections    successful    ligands    extracellular    bacterial    binding    release    theranostics    wp1    pseudomonas    site    enzymes    empty    efficacy    linkers    packages    tissue    fundamentally    therapy    pathogens    wp3    linking    anti    carriers    spp    boost    gap    biofilm    appropriate    smart    protective    cleavable    covalent    efficiency    eskape    cystic    noncovalent    potency    contact    nosocomially    noninvasive    directed    lectin    conjugates    inhibitor    intracellularly    manufacturing    infected    aeruginosa    employing    deleterious    surface    gram    overcome    resistance    envelope    linker    pipeline    wp2    threat    fibrosis    klebsiella    highest    vivo    drugs    imaging    conjugation    treatment    cellular    infection    ligand    pace    antibiotics    chronic    carbohydrate    resistances    fight    nano    lectindirecting    cargo    global    demanding    vitro    appearance    sweet    patients    sweetbullets    proteins    resistant    acting    proof    probes    bacteria    ing    relief    negative    alarmingly    mechanism    bactericidal   

Project "SWEETBULLETS" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙551 €
 EC max contribution 1˙499˙551 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙551.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Bacterial infections are now a global threat demanding novel treatments due to the appearance of resistances against antibiotics at a high pace. The ESKAPE pathogens are those with highest importance in the EU and chronic infections due to biofilm formation are a particular task. Noninvasive pathogen-specific imaging of the infected tissue is not clinically available. Its successful implementation will enable the choice of appropriate therapy and boost efficacy. Furthermore, Gram-negative bacteria have a highly protective cellular envelope as an important resistance mechanism for drugs acting intracellularly, resulting in an alarmingly empty drug-pipeline. To overcome this gap, I will establish Lectin-directed Theranostics targeting pathogens via their extracellular carbohydrate-binding proteins at the site of infection for specific imaging and treatment. This will be implemented for the highly resistant ESKAPE pathogen Pseudomonas aeruginosa through 3 different work packages. WP1 Sweet Imaging: Design & conjugation of lectin-directed ligands to imaging probes, Optimization of ligand/linker, in vivo proof-of-concept imaging study. WP2 Sweet Targeting: Delivery of antibiotics to the infection through covalent linking of lectindirecting groups. Employing different antibiotics, assessment of bactericidal potency and targeting efficiency. Manufacturing of nano-carriers with surface exposed lectin-directed ligands, noncovalent charging with antibiotics. In vitro and in vivo targeting. WP3 Sweet SMART Targeting: Conjugates as SMART drugs: specific release of anti-biofilm lectin inhibitor and drug cargo upon contact with pathogen, development of linkers cleavable by pathogenic enzymes. SWEETBULLETS will establish fundamentally novel lectin-directed theranostics to fight these deleterious infections and provide relief to nosocomially infected and cystic fibrosis patients. It is rapidly extendable towards other ESKAPE pathogens, e.g. Klebsiella spp..

 Publications

year authors and title journal last update
List of publications.
2019 Roman Sommer, Katharina Rox, Stefanie Wagner, Dirk Hauck, Sarah S. Henrikus, Shelby Newsad, Tatjana Arnold, Thomas Ryckmans, Mark Brönstrup, Anne Imberty, Annabelle Varrot, Rolf W. Hartmann, Alexander Titz
Anti-biofilm Agents against Pseudomonas aeruginosa : A Structure–Activity Relationship Study of C -Glycosidic LecB Inhibitors
published pages: 9201-9216, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01120
Journal of Medicinal Chemistry 62/20 2020-04-24
2017 Stefanie Wagner, Dirk Hauck, Michael Hoffmann, Roman Sommer, Ines Joachim, Rolf Müller, Anne Imberty, Annabelle Varrot, Alexander Titz
Covalent Lectin Inhibition and Application in Bacterial Biofilm Imaging
published pages: 16559-16564, ISSN: 1433-7851, DOI: 10.1002/anie.201709368
Angewandte Chemie International Edition 56/52 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SWEETBULLETS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SWEETBULLETS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Regen-membrane (2019)

Pulsed Electrophoretic Deposition to give Membranes for Regenerative Medicine

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

Diverge (2019)

Generation of ultra-deep libraries of transcriptional activators for gene therapy

Read More